BioWorld Asia

July 19, 2006

Actelion, Roche Sign $630M Autoimmunity Product Deal

Shrugging off recent disappointments in the clinic, Actelion AG signed what is likely to be one of the landmark licensing deals in European biotechnology in 2006. (BioWorld International) Read More

DeCode Stock Sale To Raise $30M For Multidrug Pipeline

Motility Control Proteins Might Play Part In Pancreatic Cancer

Crucell Shares Fall After Aerugen Program Ended

ProStrakan Secures Deal, Raises £11M In Placement

Nasdaq In Lead, But Potential LSE Merger Raises Questions

Cellectis, Lexicon Genetics Exchange Rights To Patents

Devices In Past, Medisys Now Complete As Investing Firm

Advanced Therapies Under Scrutiny At EU Parliament

Astion Brings In DKK50M For Dermatology Pipeline

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for April 6, 2026.

Hengrui discovers new Nav1.8 blockers

BioWorld Science

Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026

Hematopoietic stem cell research points to leukemia’s early roots

BioWorld Science

Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...

Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis

BioWorld Science

Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...